Sofiva Genomics Co.,Ltd. Stocks

Sofiva Genomics Co.,Ltd., established in 2012 and based in Taipei, Taiwan, offers a comprehensive range of genetic testing services to both domestic and international clients. The company's diverse diagnostic solutions are designed to support expectant parents, individuals with inherited conditions, and their families. Their extensive prenatal diagnostics include screenings for conditions such as thalassemia carrier status, various microdeletion syndromes, single-gene abnormalities, common chromosomal anomalies, and specific skeletal dysplasia mutations. They also provide multi-gene panel testing for inherited diseases, folate metabolism genetic analysis, carrier screening for spinal muscular atrophy (SMA) and Fragile X syndrome, congenital infection detection, preeclampsia risk assessment, maternal serum screening for Down syndrome, and karyotyping. Within the oncology sector, Sofiva Genomics delivers advanced cancer screenings, dynamic monitoring of tumor activity, and genetic evaluations for hereditary cancer predisposition. This includes specialized panels for women's cancers (breast, colon, ovarian, and endometrial), alongside human papillomavirus (HPV) screening. Furthermore, the company conducts genetic testing for rare diseases and provides specialized reproductive services such as preimplantation genetic diagnosis (PGD) and next-generation sequencing (NGS)-based preimplantation genetic screening (PGS). For newborns, their services encompass comprehensive "baby scans," screenings for hereditary sensorineural hearing loss, congenital central hypoventilation syndrome (CCHS), congenital cytomegalovirus (CMV) infection, and genetic risk assessment for atopic dermatitis. Beyond these specialized offerings, Sofiva Genomics also performs biochemical and chromosomal analyses, complemented by valuable advisory and support services for its clientele.